Proteomedix is a healthcare company specializing in advanced diagnostic solutions for prostate cancer. Its flagship product, Proclarix, is a next-generation blood test designed to provide immediate clarity for patients with elevated PSA levels. Proclarix offers a non-invasive, precise, and fast diagnosis, reducing the need for painful and costly tissue biopsies. The test can be performed using the same blood sample as PSA testing, making it accessible and convenient for both patients and physicians. By improving patient management and satisfaction, Proclarix delivers strong health economic benefits to the healthcare system. Proteomedix primarily serves patients, physicians, and healthcare providers, operating in the medical diagnostics market. The company's business model focuses on selling its diagnostic tests to healthcare institutions and laboratories, generating revenue through test sales and partnerships.

Keywords: prostate cancer, blood test, PSA levels, non-invasive, diagnosis, patient management, healthcare efficiency, diagnostic solutions, medical diagnostics, Proclarix.